CYP2D6 polymorphism in patients with eating disorders

E. M. Peñas-Lledó, P. Dorado, Z. Agüera, M. Gratacós, Xavier P. Estivill, F. Fernández-Aranda, A. Llerena

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalPharmacogenomics Journal
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Jan 2012

Fingerprint

Cytochrome P-450 CYP2D6
Alleles
Genes
Genetic Polymorphisms
Psychopathology
Personality
Serotonin
Feeding and Eating Disorders
Enzymes
Research
Pharmaceutical Preparations

Keywords

  • CYP2D6
  • eating disorders
  • pharmacogenetics
  • ultrarapid metabolizers

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Peñas-Lledó, E. M., Dorado, P., Agüera, Z., Gratacós, M., Estivill, X. P., Fernández-Aranda, F., & Llerena, A. (2012). CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics Journal, 12(2), 173-175. https://doi.org/10.1038/tpj.2010.78

CYP2D6 polymorphism in patients with eating disorders. / Peñas-Lledó, E. M.; Dorado, P.; Agüera, Z.; Gratacós, M.; Estivill, Xavier P.; Fernández-Aranda, F.; Llerena, A.

In: Pharmacogenomics Journal, Vol. 12, No. 2, 01.01.2012, p. 173-175.

Research output: Contribution to journalArticle

Peñas-Lledó, EM, Dorado, P, Agüera, Z, Gratacós, M, Estivill, XP, Fernández-Aranda, F & Llerena, A 2012, 'CYP2D6 polymorphism in patients with eating disorders', Pharmacogenomics Journal, vol. 12, no. 2, pp. 173-175. https://doi.org/10.1038/tpj.2010.78
Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill XP, Fernández-Aranda F et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics Journal. 2012 Jan 1;12(2):173-175. https://doi.org/10.1038/tpj.2010.78
Peñas-Lledó, E. M. ; Dorado, P. ; Agüera, Z. ; Gratacós, M. ; Estivill, Xavier P. ; Fernández-Aranda, F. ; Llerena, A. / CYP2D6 polymorphism in patients with eating disorders. In: Pharmacogenomics Journal. 2012 ; Vol. 12, No. 2. pp. 173-175.
@article{6d8fcc1774454c62b691b882068c4160,
title = "CYP2D6 polymorphism in patients with eating disorders",
abstract = "CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6{\%}) or two (67 vs 58.9{\%}) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2{\%}) or zero active genes (4.9 vs 6.3{\%}) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.",
keywords = "CYP2D6, eating disorders, pharmacogenetics, ultrarapid metabolizers",
author = "Pe{\~n}as-Lled{\'o}, {E. M.} and P. Dorado and Z. Ag{\"u}era and M. Gratac{\'o}s and Estivill, {Xavier P.} and F. Fern{\'a}ndez-Aranda and A. Llerena",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/tpj.2010.78",
language = "English",
volume = "12",
pages = "173--175",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - CYP2D6 polymorphism in patients with eating disorders

AU - Peñas-Lledó, E. M.

AU - Dorado, P.

AU - Agüera, Z.

AU - Gratacós, M.

AU - Estivill, Xavier P.

AU - Fernández-Aranda, F.

AU - Llerena, A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

AB - CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

KW - CYP2D6

KW - eating disorders

KW - pharmacogenetics

KW - ultrarapid metabolizers

UR - http://www.scopus.com/inward/record.url?scp=85027940350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027940350&partnerID=8YFLogxK

U2 - 10.1038/tpj.2010.78

DO - 10.1038/tpj.2010.78

M3 - Article

VL - 12

SP - 173

EP - 175

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -